A Large, Simple Trial Leading to Complex Questions.
作者信息
Harrington David P, Baden Lindsey R, Hogan Joseph W
机构信息
From the Department of Biostatistics, Harvard T.H. Chan School of Public Health, and the Department of Data Sciences, Dana-Farber Cancer Institute, Boston (D.P.H.); and the Department of Biostatistics, Brown University School of Public Health, Providence, RI (J.W.H.).
出版信息
N Engl J Med. 2021 Feb 11;384(6):576-577. doi: 10.1056/NEJMe2034294. Epub 2020 Dec 2.
Abstract
摘要
相似文献
1
A Large, Simple Trial Leading to Complex Questions.
N Engl J Med. 2021 Feb 11;384(6):576-577. doi: 10.1056/NEJMe2034294. Epub 2020 Dec 2.
2
Letter from Malaysia.
Respirology. 2021 Jun;26(6):624-626. doi: 10.1111/resp.14057. Epub 2021 Apr 11.
3
Current development of COVID-19 diagnostics, vaccines and therapeutics.
Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.
4
Audio Interview: Caring for Patients with Covid-19.
N Engl J Med. 2020 Apr 16;382(16):e50. doi: 10.1056/NEJMe2011242.
5
Prophylactic and therapeutic topical povidone-iodine in coronavirus disease 2019 (COVID-19): What is the evidence?
Int Forum Allergy Rhinol. 2020 Dec;10(12):1271-1273. doi: 10.1002/alr.22735. Epub 2020 Nov 10.
6
Type 1 interferons as a potential treatment against COVID-19.
Antiviral Res. 2020 Jun;178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.
7
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
8
[Umifenovir and coronavirus infections: a review of research results and clinical practice].
Ter Arkh. 2020 Dec 26;92(11):91-97. doi: 10.26442/00403660.2020.11.000713.
9
WHO Living Guidelines on antivirals for COVID-19 are evidence-based.
Lancet. 2022 Dec 17;400(10369):2196-2198. doi: 10.1016/S0140-6736(22)02306-6. Epub 2022 Nov 10.
10
Ten challenging questions about SARS-CoV-2 and COVID-19.
Expert Rev Respir Med. 2020 Sep;14(9):881-888. doi: 10.1080/17476348.2020.1782197. Epub 2020 Jun 30.
引用本文的文献
1
How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings.
Glob Health Med. 2025 Apr 30;7(2):96-105. doi: 10.35772/ghm.2024.01082.
2
The impact of remdesivir on SARS-CoV-2 evolution in vivo.
JCI Insight. 2025 Jan 21;10(4):e182376. doi: 10.1172/jci.insight.182376.
3
Remdesivir for the treatment of COVID-19.
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
4
XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection.
Nat Commun. 2022 Nov 16;13(1):6716. doi: 10.1038/s41467-022-34339-w.
5
Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital.
Cureus. 2021 Nov 11;13(11):e19487. doi: 10.7759/cureus.19487. eCollection 2021 Nov.
6
Identification and Development of Therapeutics for COVID-19.
mSystems. 2021 Dec 21;6(6):e0023321. doi: 10.1128/mSystems.00233-21. Epub 2021 Nov 2.
7
SARS-CoV-2-host proteome interactions for antiviral drug discovery.
Mol Syst Biol. 2021 Nov;17(11):e10396. doi: 10.15252/msb.202110396.
8
On aerosol transmission of SARS-CoV-2.
J Family Med Prim Care. 2021 Aug;10(8):3161-3162. doi: 10.4103/jfmpc.jfmpc_695_21. Epub 2021 Aug 27.
9
Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes.
Environ Microbiol. 2021 Nov;23(11):6364-6376. doi: 10.1111/1462-2920.15769. Epub 2021 Sep 22.
10
Remdesivir for the treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
Zotero 插件